Cargando…
Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
JNJ-Q2 is a novel, fifth-generation fluoroquinolone that has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsible for acute bacterial skin and skin structure inf...
Autores principales: | Jones, Travis M, Johnson, Steven W, DiMondi, V Paul, Wilson, Dustin T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908938/ https://www.ncbi.nlm.nih.gov/pubmed/27354817 http://dx.doi.org/10.2147/IDR.S105620 |
Ejemplares similares
-
A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia
por: Covington, Paul S., et al.
Publicado: (2013) -
Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
por: Leviton, Ira M., et al.
Publicado: (2022) -
Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012) -
Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015) -
Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections
por: Wilcox, Mark H, et al.
Publicado: (2021)